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1. Introduction
   Intimate male partner violence (IPV) refers to actual or 
threatened physically, psychologically or sexually abusive 
acts committed against women by their current or former 
male partners. IPV is considered a chronic social stressor 
for women as this kind of abusive relationships can last 
for decades[1-3]. Social stress, defined as the stress derived 
from a social interaction among members in same species, 
is considered the main source of stress in human beings 
and, consequently, increases the risk of developing health 
alterations[4-6]. 
Cross-sectional, prospective and retrospective studies have 
consistently demonstrated that living with a violent intimate 
male partner is a significant contributor to women’s adverse 
mental and physical health outcomes. Studies which 
compare women exposed to IPV with those who are not show 
that common mental sequelae include depression, post-
traumatic stress disorder (PTSD), anxiety, suicidal behavior, 
sleep and eating disorders, low self-esteem, personality 
disorders, increased likelihood of substance abuse, and 
social dysfunction[1,7-18]. To our knowledge, there are few 
studies that have tried to assess mental health profiles 
on IPV women victims by examining patterns of distress 
and adjustment[19]. Thus, it is clearly important to assess 
individual differences to the deleterious effects of IPV on 
mental health following a person-oriented perspective[17,19-
24]. Recent studies have found depressive symptomatology 
following IPV in 54% to 78%, and PTSD in 18% to 74% of 
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women victims. Furthermore, these women have often 
comorbid disorders such as mood, anxiety and/or substance 
abuse disorders[15,17,19,25,26]. IPV has also a great impact 
on women’s physical health with short- and long-term 
consequences. First, in case of physical violence, the most 
common and immediate consequences are injuries, and 
neurological sequelae of violent acts. However, it is the fear 
and stress experienced through violence that results in long-
term chronic stress-related physical problems. In general, 
abused women report a low self-perceived health[2,27-29], 
and higher incidence of different signs somatic symptoms, 
and illnesses related to the cardiovascular, gastrointestinal, 
muscular, urinary, and reproductive systems[2,30,31]. The 
most frequent health problems reported in IPV studies 
are headaches, nightmares, loss of appetite, back, pelvic, 
muscular and stomach pain, hypertension, asthma, diabetes, 
and gynecological symptoms[2,31-34]. Futhermore, other 
physical disturbances have been studied such as different 
markers of immune system functioning[35,36], with different 
results depending on the violence experienced and other 
mediating factors.
   IPV is a chronic stressful experience with high impact 
on women’s health, as it has been widely endorsed in the 
literature[2,27,37]. With this in mind, the hypothalamic-
pituitary-adrenocortical (HPA) axis is the mechanism by 
which stress regulates its physiological response, and a large 
number of studies include its markers to measure its impact. 
This is the main reason why cortisol (and also, but not so far 
DHEA), the hormone released during the stress response, 
is one of the most studied biomarker and recognized to 
have an impact on the rest of body systems[38-40]. In this 
sense, studies have associated hormone levels with mental 
health status. It has been demonstrated the impact of IPV on 
women’s HPA axis[1,25,26,41-45]. Studies that compared non-
traumatized healthy women with female victims of IPV found 
different results. While Griffin et al.[25], reported lower early 
morning plasma cortisol levels in female victims, Basu et 
al.[1], found no differences between non-traumatized and 
female victims. On the other hand, the comparison between 
female victims of IPV found a variety of results depending 
on the incidence of PTSD and/or depression. While some 
studies found higher cortisol levels in women with current 
PTSD[26] or even remitted PTSD[43], another study reported 
no difference between female victims with PTSD and those 
without it[45], and Griffin et al.[25], found lower cortisol levels 
in female victims with PTSD. Furthermore, those studies that 
compared female victims with PTSD and those with a co-
morbid PTSD/depression found no differences[1,25]. 
   Most studies have assessed the impact on IPV on women 
victims considered as a homogeneous group in comparison 
with nonabused women. However, studies on stress impact 
have started to assess individual differences on this 
impact related to factors of resilience and vulnerability as 
well as the different strength of the stress variables. This 
consideration of women victims as an homogeneous group 
has produced misunderstanding in professionals that deal 
with the care of these women, the health intervention as 
well as the justice system. Thus, it is necessary to start 
research on individual differences in the impact that IPV 
has on women victims’ health. This approach would allow a 
more effective intervention in several levels (health system, 
advocacy, social services).
   The aim of this study was twofold to analyse the individual 
differences in the impact that IPV has on a woman’s mental 
and physical health and to determine the association of 
the different profiles of health impact with cortisol and 
dehydroepiandrosterone (DHEA) basal saliva levels. 
2. Material and methods 
2.1. Subjects
   The present study is part of a larger research project on 
the impact of IPV on women’s health carried out in the 
Valencian Community of Spain[15,46,47]. All participants were 
of Spanish nationality. Female victims of IPV (n=73) were 
recruited from the 24 h centers for helping women (which 
offer information, and help from lawyers and social workers, 
and some psychological interventions for the women) in 
the three provinces of the Valencian Community of Spain 
(Alicante, Castellon and Valencia). A control group of women 
not exposed to IPV (n=31) was recruited through women’s 
clubs (a civil organization located in each city and town 
that only women can join and in which they develop a wide 
arrange of activities such as receiving information, courses, 
trips, etc.). 
2.2. Ethical considerations
   The study was approved by the University of Valencia 
research ethics committee, and prior informed written 
consent was obtained from all participants. Subjects 
did not receive any money or other inducement for their 
participation.
2.3. Procedure
   The study consisted of a structured interview in which 
trained female psychologists asked women questions 
about their lives and health. In general, each woman 
was interviewed four to six times, and the duration of 
each session was approximately 1.5 h. A comprehensive 
questionnaire was designed for use in a face-to-face 
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interview. The majority of questions were designed to 
obtain objective factual reports. Additionally, women 
were asked to provide saliva samples for hormonal assays 
(details below).
2.4. Questionnaires
   The questionnaires from which information for the present 
study was obtained are described below, and more detailed 
information is given in our previous articles[44,46]. 
   The sociodemographic profile included age, education-
level and marital status items. The relationship with the 
aggressor/partner included data on the cohabitation with 
him at the time of the interviews and during the last year.
2.5. Characteristics of intimate male partner violence
   A questionnaire was constructed to obtain detailed 
information about the different types of violence (physical, 
psychological and sexual) toward the women perpetrated 
by their partners (see 46 for more detailed information). 
Women gave answers of either “yes” or “no” regarding the 
experience of each act. 
2.6. Mental health assessment 
   The Beck Depression Inventory (BDI) was used to assess 
depressive symptoms[48], and the total scores on the BDI 
ranged from 0 to 63. Women with BDI scores ranging 
from 0 to 8 were considered as having no symptoms of 
depression, from 9 to 18 as mild, from 9 to 29 as moderate, 
and from 30 to 63 to severe depressive symptoms. The 
Spanish version of the BDI that was used in our study has 
been validated by Conde and Useros[49], who obtained 
an internal consistency coefficient of 0.88. In our study, 
the cut-off score was set to 18. The incidence and 
severity of symptoms of current PTSD were assessed with 
Echeburúa’s Severity of Symptom Scale of Posttraumatic 
Stress Disorder[50]. This is a structured interview based 
on DSM-IV criteria. The instrument has a high internal 
consistency with a Cronbach’s α coefficient of 0.92 and a 
high test-retest reliability as well as a good discriminant, 
concurrent, and construct validity. A stressor was 
assessed by asking the woman if she had experienced 
an unusual, extremely distressful event (irrespective of 
whether or not it was IPV-related). Either type of event 
was considered a qualifying trauma when it met the 
DSM-IV criteria for PTSD and when distressing symptoms 
persisted for at least 4 weeks. Women were also asked 
about the lifetime incidence of thoughts and attempts 
of suicide. Detailed information about women’s mental 
health assessment is given in Picó-Alfonso et al[15].
2.7. Physical health assessment
   Self-report physical health status was assessed using a 
questionnaire designed by the research team. A symptom 
is defined as a subjective evidence of physical disturbance 
observed by the patient. The symptom inventory consisted of 
35 symptoms and women were queried about their incidence 
in the year preceding the study. Furthermore, a total number 
of symptoms as well as a summatory of specific system 
symptoms was also calculated.
2.8. Saliva samples 
   Saliva samples for the analysis of the level of cortisol and 
DHEA were also collected. The participants provided a 
minimum of 0.5 mL of saliva in a plastic tube twice a day 
(between 08:00 and 09:00, and between 20:00 and 21:00) for 
four consecutive days at home, starting the fourth day after 
the beginning of menstruation. Saliva samples were frozen in 
women’s freezer and brought to the freezer of the Department of 
Psychobiology in a mobile freezer, and then kept frozen at -21 
曟. Finally, all samples were sent to the Department of Clinical 
Neurosciences at University of Cambridge, UK, for analysis. 
2.8.1. Hormone assays
   Cortisol was measured by validated ELISA on 20 μL 
samples of saliva (antibody Cambio UK) without extraction 
(intra-assay variation: 4.1%; inter-assay: 7.6%). DHEA 
was measured by validated radioimmunoassay on 333 μL 
samples after extraction into hexane/ether (4:1) (antibody 
Bioclin; intra-assay variation: 5.1%; inter-assay: 11.2%). 
Details are given in Harris et al.[51]. Data from the four daily 
morning and evening collections were summed to give a 
mean value at each time point.
2.9. Statistical analyses
   Women were classified into four groups depending on the 
incidence of IPV and their mental health status: non-abused 
women, and abused women with no depressive or PTSD 
symptoms (IPV-no symptoms), with depressive symptoms 
(IPV-depressive symptoms), and with both depressive and 
PTSD symptoms (IPV-depressive/PTSD symptoms). The four 
groups were compared with respect to age, and the profile 
of physical symptoms and mental health status using One-
way analysis of variance (ANOVAs). Regarding the level 
of education, marital status, types of IPV, the incidence 
of clinical depression and PTSD the comparisons were 
assessed by using Pearson’s Chi-square tests. Comparisons 
between groups with respect to endocrine measures (cortisol 
and DHEA analysis were carried out after logarithmic 
transformation of the data) were assessed by ANOVAs with 
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Bonferroni post hoc comparisons. When the criteria of 
ANOVA were not fulfilled, Welch’s tests were calculated, 
and Games-Howell post hoc comparisons applied. A 
significance level of P<0.05 was established for all analyses. 
All statistical analyses were conducted using the SPSS for 
Windows statistical package Version 19.0. 
3. Results
3.1. Participant’s characteristics and health profiles
   There were no differences between groups in either 
age (Vw[3, 49.13]=1.25) or education [χ
2 
(18, N=104)=16.60] 
(Table 1). There was a significant association between the 
marital status and group [χ2 (12, N=104)=33.40, P<0.001]. 
The percentage of “married” women was higher than 
expected by chance in the non-abused group, whereas the 
contrary pattern was observed in the category of “separated/
divorced”. There were no significant association between 
this variable and any of the three IPV-groups [χ2 (8, N= 
73)=9.63]. On the other hand, there was a significant 
association between the cohabitation with the aggressor/
partner at the time of the interviews and the group [χ2(3, N= 
104)=19.95, P<0.001]. The proportion of women cohabiting 
with the aggressor/partner was significantly higher than 
expected in the nonabused group (96.8%) and lower in the 
IPV-no symptoms group (42.1%). However, this was not 
apparent during the year previous to the interviews [χ2(3, 
N=104)=5.43]. In the IPV-groups, there was no significant 
association between the cohabitation and the group either 
during the previous year [χ2(2, N=73)=3.06] or at the time of 
the interviews: [χ2 (2, N=73)=1.47].
   All women (100%) in the IPV groups were exposed to 
psychological abuse by their partners. Furthermore, over a 
half of women on each IPV group were physically abused, 
and around one third of them were sexually abused by their 
partners. There was no association between the incidence of 
physical and sexual abuse and the mental health profile of 
women victims of IPV: physical [χ2(2, N=73)=2.19, n.s.], and 
sexual [χ2(2, N=73)=1.33]. 
3 .2 .  Di f f e r en t  p ro f i l e s  o f  dep re s s i v e  and  PTSD 
symptomatology 
   One hundred and four women participated in this study. 
Seventy three were female victims of IPV and 31 were 
women no exposed to IPV (non-abused women). Depending 
on the incidence of symptoms of depression and PTSD 
female victims were distributed into three groups: (1) Female 
victims of IPV with no symptoms of depression or PTSD 
(IPV-no symptoms group; n=19); (2) Female victims of IPV 
Table 1
Characteristics of nonabused women and women victims of intimate male partner violence with no symptoms, depressive symptoms, and 




No symptoms Depressive Depressive/PTSD
n=19 n=36 n=18
Age (mean依SD) 46.03依12.92 49.42依10.50 43.75依10.61 47.00依8.50 n.s.
Education level 
Illiterate 0 0 0 5.6
Able to read and write 3.2 15.8 13.9 5.6
Uncompleted primary school 12.9 26.3 19.4 33.3
Primary school 35.5 36.8 38.9 33.3
Secondary school 38.7 15.8 19.4 16.7
University studies: 3-4 years 3.2 5.3 2.8 0
University studies: 5-6 years 6.5 0 5.6 5.6
Marital status P<0.001
Widow 3.2 10.5 0 5.6
Single not living with partner 0 15.8 8.3 11.1
Separated/Divorced from husband 0 31.6 47.2 22.2
Single living with partner 9.7 0 2.8 11.1
Married 87.1 42.1 41.7 50
Cohabitation with aggressor/partner
At time of interviews 96.8 42.1 55.6 61.1 P<0.001
During the last year 96.8 78.9 94.4 88.9 n.s.
Intimate partner violence
Physical − 52.6 72.2 61.1 n.s.
Psychological  − 100 100 100 n.s.
Sexual − 21.1 27.8 27.8 n.s.
IPV: Intimate male partner violence; PTSD: Posttraumatic stress disorder; n.s.: Not significant.
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with symptoms of depression (IPV-depressive group; n=36), 
and (3) Female victims of IPV with symptoms of depression 
and PTSD (IPV-depressive/PTSD group; n=18). None of the 
non-abused women had either symptoms of depression or 
PTSD (non-abused group; n=31). 
   The scores for depression were significantly higher 
in both the IPV-depressive and the IPV-depressive/
PTSD groups than in the IPV-no symptoms and non-
abused groups (P<0.001). Moreover, the IPV-depressive/
PTSD group had higher scores than the IPV-depressive 
group (P<0.05). In the IPV-depressive group women were 
distributed mainly among “mild” (72.2%) symptoms, 
while the highest level of severity was found in IPV-
depressive/PTSD group: 38.9% of women suffered “severe” 
symptoms, these percentages being higher than expected 
by chance in both groups. On the other hand, PTSD scores 
were significantly higher, not only in those with clinical 
PTSD, but also in the IPV-depressive group than in the 
IPV-no symptoms and non-abused groups (P<0.001). 
Furthermore, the IPV-depressive/PTSD group had higher 
scores than all the other groups (P<0.001). Regarding 
suicide, the incidence of both suicidal thoughts and 
attempts was associated with the group: thoughts [χ2 (3, 
N=104)=28.67, P<0.001] and attempts [χ2(3, N=104)=12.21, 
P<0.01]. In the case of thoughts, the incidence was 
higher than expected in both IPV-depressive and IPV-
depressive/PTSD groups, and only in the latter group 
regarding suicidal attempts. On the contrary, the 
incidence of both thoughts and attempts of suicide were 
lower than expected in the nonabused group (Table 2). 
3.3. Association of the different profiles of mental health 
dysfunction with physical health
 
   The four groups of women were compared with regards to 
the incidence of perceived physical symptoms during the 
year prior to the interviews. Detailed information of total 
amount of physical symptoms as well as the incidence of 
each specific symptom is given in Table 3.  
   There were differences between groups in the total amount 
of physical symptoms (Vw [3, 44.14]=52.71; P<0.001). Post hoc 
comparisons indicated that the IPV-depressive/PTSD group 
had higher incidence of symptoms than the other three 
groups (P<0.001), and the IPV-depressive group showed 
a higher mean than non-abused (P<0.001) and IPV-no 
symptoms group (P<0.05). 
   There were differences between groups in the total amount 
of symptoms of specific systems: nervous (Vw [3, 45.28]= 
38.02; P<0.001), muscular (Vw [3, 48.13]=26.39; P<0.001), 
reproductive (F [3, 103]=4.04; P<0.01), digestive (Vw [3, 44.92] 
=14.25; P<0.001), circulatory (Vw [3, 44.30]=22.38; P<0.001) 
and the endocrine system (Vw [3, 41.83]=60.92; P<0.001) with 
the only exception of urinary system and skin (F [3, 103] 
=0.60). Post hoc comparisons showed a higher amount of 
symptoms in both IPV-depressive/PTSD and IPV-depressive 
groups than in the non-abused group (P<0.001, reproductive 
system: P<0.05). The IPV-depressive/PTSD group showed 
a higher amount of symptoms in nervous, muscular and 
endocrine systems (P<0.001), as well as in digestive and 
circulatory systems (P<0.05) than the IPV-no symptom 
group, and a higher number of symptoms in nervous and 
Table 2




No symptoms Depressive Depressive/PTSD
n=19 n=36 n=18
BDI 3.26依3.16 4.11依3.00 16.25依5.21***/aaa 27.06依12.96***/aaa/b P<0.001
Clinical cut-off - - 27.8 66.7 P<0.01
Severity of depressive symptoms   P<0.001
No depression - - 0 0  
Mild - - 72.2 33.3  
Moderate - - 25.0 27.8  
Severe - - 2.8 38.9  
PTSD - - - 100
Total score  1.77依2.91 3.26依3.46 11.44依5.25***/aaa 29.11依8.15***/aaa/bbb P<0.001
Subscales PTSD score    
Re-experiencing 0.94依1.46 1.26依1.48 3.75依2.92***/aaa 9.00依2.74***/aaa/bbb P<0.001
Avoidance 0.61依1.89 1.05依1.31 4.14依3.01***/aaa 10.89依4.17***/aaa/bbb P<0.001
Arousal 0.23依0.56 0.95依1.39 3.56依2.25***/aaa 9.22依2.65***/aaa/bbb P<0.001
Suicidal thoughts 3.2 31.6 52.8 72.2 P<0.001
Suicidal attempts 3.2 10.5 27.8 38.9 P<0.01
IPV: Intimate male partner violence; PTSD: Posttraumatic stress disorder; BDI: Beck depression inventory.
***: Differs from nonabused group, P<0.001; aaa : Differs from IPV-No symptoms group, P<0.001; b : Differs from IPV-Depressive group, P<0.05; 
bbb: P<0.001.
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endocrine systems than the IPV-depressive group (P<0.001). 
Furthermore, IPV-depressive group showed a higher amount 
of muscular symptoms than the IPV-no symptom group 
(P<0.05). The only difference between IPV-no symptoms and 
the non-abused group was a higher amount of symptoms in 
the endocrine system in the former group (P<0.05).
   Twenty-six specific symptoms out of 35 were significantly 
associated with the group: headache [χ2 (3, N=104)=15.87, 
P<0.001], faintness [χ2 (3, N=104)=26.58, P<0.001], 
numbness [χ2 (3, N=104)=27.85, P<0.001], trembling 
hands [χ2 (3, N=104)=27.05, P<0.001], ringing ears [χ2(3, 
N=104)=21.51, P<0.001], dizziness [χ2 (3, N=104)=21.14, 
Table 3
Physical symptoms suffered by nonabused women and women victims of violence with no symptoms, depressive symptoms, and depressive and 




No symptoms Depressive Depressive/PTSD
n=19 n=36 n=18
Total physical symptoms 4.16依3.43 8.16依6.61    13.50依5.30***/a          19.17依4.97***/aaa/bbb P<0.001
Nervous system 0.97依1.30 2.26依2.13     3.64依2.27***            5.89依1.78***/aaa/bbb P<0.001
   Headache 32.3 42.1 72.2 77.8 P<0.001
   Faintness 19.4 36.8 47.2 94.4 P<0.001
   Numbness 3.2 26.3 47.2 72.2 P<0.001
   Trembling hand 6.5 26.3 41.7 77.8 P<0.001
   Ringing ears 9.7 31.6 27.8 72.2 P<0.001
   Dizziness 16.1 21.1 41.7 77.8 P<0.001
   Blurred vision 6.5 26.3 47.2 44.4 P<0.01
   Nightmares 3.2 15.8 38.9 72.2 P<0.001
Muscular system 1.19依1.25 1.89依1.59     3.14依1.44***/a        4.00依1.03***/aaa P<0.001
   Low energy 12.9 42.1 75.0 83.3 P<0.001
   Fatigue 12.9 31.6 47.2 83.3 P<0.001
   Cramp 16.1 21.1 41.7 50.0 P<0.05
   Muscular pain 29.0 36.8 69.4 88.9 P<0.001
   Back pain 48.4 57.9 80.6 94.4 P<0.01
Reproductive system 0.39依0.72 0.68依1.16 1.03依0.91* 1.22依1.06* P<0.01
   Amenorrhoea 3.2 10.5 8.3 5.6 n.s.
   Menstrual pain 19.4 21.1 22.2 27.8 n.s.
   Vaginal bleeding 6.5 5.3 16.7 11.1 n.s.
   Vaginal pain 3.2 15.8 19.4 27.8 n.s.
Painful intercourse 6.5 10.5 22.2 27.8 n.s.
   Pelvic pain 0.0 5.3 14.3 23.5 P<0.05
Digestive system 1.00依1.06 1.53依1.65    2.69依1.82***      3.39依1.61***/aa P<0.001
   Nausea 19.9 21.1 30.6 55.6 P<0.05
   Vomiting 9.7 0.0 25.0 44.4 P<0.01
   Heartburn 16.1 15.8 41.7 61.1 P<0.01
   Stomach pain 12.9 21.1 41.7 72.2 P<0.001
   Diarrhea 6.5 10.5 11.1 38.9 P<0.05
   Constipation 16.1 47.4 38.9 22.2 n.s.
   Bloating 25.8 21.1 55.6 38.9 P<0.05
   Anal bleeding 0.0 15.8 25.0 5.6 P<0.05
Urinary system   
   Leakage of urine 0.0 10.5 22.2 33.3 n.s.
Circulatory system 0.16依0.45 0.58依0.69   1.11依0.75***     1.50依0.79***/aa P<0.001
   Chest pain 6.5 42.1 61.1 72.2 P<0.001
   Palpitations 9.7 15.8 50.0 77.8 P<0.001
Respiratory system   
Shortness of breath 9.7 21.1 47.2 66.7 P<0.001
Skin 0.16依0.45 0.16依0.37 0.19依0.47 0.33依0.59 n.s.
   Pruritus 6.5 5.3 11.1 16.7 n.s.
   Eruptions 9.7 10.5 8.3 16.7 n.s.
Endocrine system 0.10依0.30  0.74依0.87*     1.00依0.89***            1.83依0.51***/aaa/bbb P<0.001
   Weight change 6.5 36.8 52.8 88.9 P<0.001
   Appetite lost 3.2 36.8 47.8 94.4 P<0.001
*: Differs from nonabused group, P<0.05; ***: P<0.001. a: Differs from no symptoms group, P<0.05; aa: P<0.01; aaa: P<0.001. bbb: Differs from 
depressive group, P<0.001.
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P<0.001], blurred vision [χ2 (3, N=104)=14.94, P<0.01], 
nightmares [χ2 (3, N=104)=27.95, P<0.001], low energy [χ2 
(3, N=104)=34.44, P<0.001], fatigue [χ2 (3, N=104)=24.83, 
P<0.001], muscular pain [χ2 (3, N=104)=22.35, P<0.001], 
back pain [χ2 (3, N=104)=15.01, P<0.01], pelvic pain [χ2 
(3, N=104)=8.05, P<0.05], nausea [χ2 (3, N=104)=10.88, 
P<0.05],  vomiting [χ 2 (3,  N=104)=14.48, P<0.01], 
heartburn [χ2 (3, N=104)=14.26, P<0.01], stomach pain [χ2 
(3, N=104)=20.04, P<0.001], diarrhea [χ2 (3, N=104)=10.88, 
P<0.05], bloating [χ2 (3, N=104)=9.02, P<0.05], anal 
bleeding [χ2 (3, N=104)=10.55, P<0.05], chest pain [χ2 (3, 
N=104)=27.95, P<0.001], palpitations [χ2 (3, N=104)=29.19, 
P<0.001], shortness of breath [χ2 (3, N=104)=20.76, 
P<0.001], weight change [χ2 (3, N=104)=34.18, P<0.001], 
and appetite lost [χ2 (3, N=104)=40.43, P<0.001], with the 
exception of most symptoms of the reproductive system: 
amenorrhoea [χ2 (3, N=104)=1.23], menstrual pain [χ2 
(3, N=104)=0.48], vaginal bleeding [χ2 (3, N=104)=2.54], 
vaginal pain [χ2 (3, N=104)=6.10], painful intercourse 
[χ2 (3, N=104)=5.32], constipation [χ2 (3, N=104)=7.31], 
leakage of urine [χ2 (3, N=104)=5.41], pruritus [χ2 (3, 
N=104)=1.89] and eruptions [χ2 (3, N=104)=0.92] (Table 3). 
   The incidence of the following symptoms was higher 
than expected by chance in the IPV-depressive/PTSD 
group: headache, faintness, numbness, trembling 
hands, ringing ears, dizziness, nightmares, low energy, 
fatigue, muscular pain, back pain, pelvic pain, nausea, 
vomiting, heartburn, stomach pain, diarrhea, chest 
pain, palpitations, shortness of breath, weight change, 
and loose of appetite. Also in the IPV-depressive group 
eight symptoms had a higher incidence than expected: 
headache, blurred vision, low energy, muscular pain, 
bloating, anal bleeding, chest pain, palpitations, and 
shortness of breath. On the contrary, just two symptoms, 
vomiting and palpitations, had a lower incidence than 
expected in IPV-no symptoms group. Regarding non-
abused group, almost all symptoms showed a lower 
incidence than expected, with the exception of vomiting, 
diarrhea, and bloating.
3.4. Association of the different profiles of mental health 
dysfunction with cortisol and DHEA basal saliva levels 
   The four groups of women were compared with regards 
to the basal level of cortisol and DHEA as well as the 
ratio cortisol/DHEA (C/DHEA). Mean basal levels and 
comparisons between groups are given in Table 4. There 
were significant differences in mean morning and evening 
cortisol levels between the groups [ANOVA: morning: F 
[3, 103]=4.14; P=.008; evening: Vw [3, 42.89]=5.34; P=.003 
F (1, 115)]. Post hoc comparisons revealed that morning 
levels were lower in the IPV-depressive group than in the 
IPV-no symptoms group (P<0.05), while evening cortisol 
levels were significantly higher in IPV-depressive group 
than in the non-abused group (P<0.01). Both morning 
and evening DHEA were significantly different between 
groups (morning: F [3, 103]=4.51; P=0.005); evening: Vw [3, 
45.19]=4.45; P=0.008). Post hoc comparisons showed that 
both morning and evening DHEA levels were higher in 
the IPV-depressive group than in the non-abused group 
(P<0.01). 
   As it is shown in Figure 1, morning C/DHEA ratio was 
significantly different between the groups (Vw [3,48.86]=7.51; 
P<0.001). Post hoc comparisons indicated that the ratio was 
lower in the IPV-depressive group than in all the other 
groups (non-abused: P<0.001; IPV-no symptoms: P<0.05; 
and IPV-depressive/PTSD: P<0.01). 
Table 4
Basal saliva levels of cortisol, DHEA (ng/ml, and ratio C/DHEA (nMol/L in the morning and evening in Nonabused women and women victims 
of Intimate male partner violence with no symptoms, depressive symptoms, and depressive/posttraumatic stress disorder symptoms. (Mean and 
standard deviation, SD.
 Variable  Nonabused
n=31
IPV P value
No symptoms Depressive Depressive/PTSD
n=19 n=36 n=18
Cortisol (ng/mL)      
AM 2.93依1.11 3.38依1.14 2.34依1.02a 3.31依1.62 P<0.01
PM 0.37依0.14 0.58依0.58 0.83依0.67** 0.67依.53 P<0.01
DHEA(ng/mL)     
AM 0.34依0.22 0.48依0.31 0.63依0.43** 0.43依.29 P<0.01
PM 0.20依0.09 0.34依0.35 0.44依0.38** 0.28依0.25 P<0.01
RATIO C/DHEA (nMol/L)     
AM 7.87依4.20 7.31依5.64 4.09依3.34***/a/bb 8.72依6.41 P<0.001
PM 1.59依0.72 1.42依0.76 1.99依2.14 2.42依2.23 n.s.
IPV: Intimate male partner violence; PTSD: Posttraumatic stress disorder;  n.s.: Not significant.
**: Differs from nonabused group, P<0.01; ***: P<0.001. a: Differs from IPV-No symptoms group, P<0.05. bb: Differs from IPV-Depressive/PTSD 
group, P<0.01.

























Figure 1. Mean±SD of morning C/DHEA ratio (nMol/L) in evening in 
nonabused women and women victims of intimate male partner violence with 
no symptoms, depressive symptoms, and depressive/posttraumatic stress 
disorder symptoms.   
***: Differs from nonabused group; P<0.001, IPV-No symptoms; P<0.05, and 
IPV-depressive/PTSD; P<0.01.
4. Discussion
   Our results show that there are individual differences in 
the impact that the exposure to IPV has on women’s health. 
Thus, while some women show no symptoms of either 
depression or PTSD (the IPV-no symptoms group), others 
develop mostly mild depression (IPV-depressive group), 
and the rest women a comorbid more severe depression 
and PTSD (IPV-depressive/PTSD group). Thus, exposure 
to IPV does not necessarily lead to the development of 
psychopathology in all women or to a unique pattern of 
mental ill-health. A more detailed assessment of mental 
health in female victims may aid the design of appropriate 
intervention policies[15,19,20,23,24].  
   With respect to physical health there is an association 
between the amount of somatic symptoms and mental health 
deterioration profile. The main results shown that the IPV-
depressive/PTSD group had the highest incidence in the 
total amount of symptoms followed by the IPV-depressive 
group in comparison with the IPV-no symptoms group 
and the non-abused group. Furthermore, the incidence 
of the specific symptoms headache, faintness, numbness, 
trembling hands, ringing ears, dizziness, nightmares, low 
energy, fatigue, muscular pain, back pain, pelvic pain, 
nausea, vomiting, heartburn, stomach pain, diarrhea, chest 
pain, palpitations, shortness of breath, weight change, and 
loose of appetite was higher than expected by chance in 
the IPV-depressive/PTSD group, while headache, blurred 
vision, low energy, muscular pain, bloating, anal bleeding, 
chest pain, palpitations, and shortness of breath was higher 
than expected by chance in the IPV-depressive group. 
These results are consistent with other studies that analyzed 
physical symptomatology in women victims[32,34].
   Finally, there is also an association between levels of stress 
hormones and mental health deterioration. A disturbed 
HPA axis could either reflect or contribute to the array of 
mental stress-related disorders[40,52-54]. Our results clearly 
demonstrate that dysregulation of the HPA axis and basal 
levels of DHEA are particularly associated with depressive 
symptoms in women exposed to IPV. The IPV-depressive 
group had lower morning cortisol levels than the IPV-no 
symptoms group but higher evening cortisol levels and both 
higher morning and evening DHEA levels in comparison to 
the nonabused group. More significantly, they had a lower 
morning cortisol/DHEA ratio than all the other groups. 
However, no significant alterations compared to non-abused 
controls were found in those women with neither depressive 
nor PTSD symptoms (IPV-no symptoms) or those with 
comorbidity of these two disorders (IPV-depressive/PTSD 
group). Previous studies reported that female victims of IPV 
who developed PTSD had higher morning levels of cortisol 
than those that did not[25,26,43]. However, in general, studies 
on cortisol in patients with PTSD have revealed inconsistent 
results, while some studies reported no differences in 
cortisol levels between individuals with PTSD and controls 
or between trauma-exposed subjects with and without PTSD, 
and even others found higher levels[55-58]. On the other hand, 
the comorbidity of major depressive disorder and PTSD 
has received scant attention[59], studies reporting a variety 
of results[60-62]. The meta-analysis conducted by Morris et 
al.[63], on 47 studies revealed that daily cortisol output was 
lower in trauma-exposed individuals with comorbid major 
depressive disorder/PTSD in comparison to controls. Our 
results suggest that cortisol is altered specifically in those 
with depressive symptoms alone following IPV. It is not 
clear whether this indicates a distinct psychopathological 
state, or whether altered cortisol in some way influences 
the psychological response to IPV. It is possible that the 
presence of the two sets of symptoms in our subjects have 
opposite actions on cortisol, though we had no women with 
PTSD alone. This cannot be verified from our data. Since the 
risk for depression as well as depression itself, is associated 
with higher morning cortisol, it is unclear whether our 
results reflect an epiphenomenon of depressed state, or an 
antecedent risk for it. 
   Both lower and higher levels of DHEA have been reported 
in depressed subjects in comparison to controls[64-68]. It is 
interesting, in view of the finding that altered cortisol was 
restricted to the IPV-depressive group, that this was also the 
group in which DHEA was altered in comparison to controls. 
The high levels found in women of the IPV-depressive 
group in our study may have some protective effects against 
putative deleterious actions of cortisol[69]. However, as this is 
a cross-sectional study, it was not possible to assess whether 
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high levels of DHEA predicted a reduced incidence of 
depressive symptoms. Since altered cortisol and DHEA was 
limited to the IPV-depressive group, their C/DHEA ratio was 
also altered, as would be expected. Elevated C/DHEA ratios 
have reported as a state marker of depressive illness[64,70,71]. 
   The present results indicate that women exposed to IPV 
show differences in the vulnerability and resilience to the 
development of psychopathology, somatic symptoms as well 
to the alterations in the endocrine system[71], and the two 
may be related. What makes some women more vulnerable 
to develop specific IPV-related health deterioration and 
others resilient is not well understood. Thus, discovering 
those variables that may contribute to the different 
vulnerability and resilience to develop health deterioration 
is important for advancing diagnostic screening, prevention 
and treatment[21,24,72,73]. 
   A limitation of this study consists on the method used for 
the recruitment of the sample. Women victims of IPV were 
recruited from the Centers for Helping Women, while the 
recruitment from other settings such as Primary health care 
could gather a wider sample of victims.
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